Search Results - "Schmidt, Michael M."

Refine Results
  1. 1

    A modeling analysis of the effects of molecular size and binding affinity on tumor targeting by Schmidt, Michael M, Wittrup, K Dane

    Published in Molecular cancer therapeutics (01-10-2009)
    “…A diverse array of tumor targeting agents ranging in size from peptides to nanoparticles is currently under development for applications in cancer imaging and…”
    Get full text
    Journal Article
  2. 2

    Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance by Thurber, Greg M., Schmidt, Michael M., Wittrup, K. Dane

    Published in Advanced drug delivery reviews (01-09-2008)
    “…Antibodies have proven to be effective agents in cancer imaging and therapy. One of the major challenges still facing the field is the heterogeneous…”
    Get full text
    Journal Article
  3. 3

    Practical theoretic guidance for the design of tumor-targeting agents by Wittrup, K Dane, Thurber, Greg M, Schmidt, Michael M, Rhoden, John J

    Published in Methods in enzymology (2012)
    “…Theoretical analyses of targeting agent pharmacokinetics provides specific guidance with respect to desirable design objectives such as agent size, affinity,…”
    Get more information
    Journal Article
  4. 4
  5. 5

    Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability by Schmidt, Michael M., Thurber, Greg M., Wittrup, K. Dane

    Published in Cancer Immunology, Immunotherapy (01-12-2008)
    “…Theoretical analyses suggest that the cellular internalization and catabolism of bound antibodies contribute significantly to poor penetration into tumors…”
    Get full text
    Journal Article
  6. 6

    Intratumorally anchored cytokine therapy by Wittrup, K Dane, Kaufman, Howard L, Schmidt, Michael M, Irvine, Darrell J

    Published in Expert opinion on drug delivery (03-06-2022)
    “…On-target, off-tumor toxicity severely limits systemic dosing of cytokines and agonist antibodies for cancer. Intratumoral administration is increasingly being…”
    Get more information
    Journal Article
  7. 7

    Monovalent, reduced-size quantum dots for imaging receptors on living cells by Ting, Alice Y, Howarth, Mark, Liu, Wenhao, Puthenveetil, Sujiet, Zheng, Yi, Marshall, Lisa F, Schmidt, Michael M, Wittrup, K Dane, Bawendi, Moungi G

    Published in Nature methods (01-05-2008)
    “…We describe a method to generate monovalent quantum dots (QDs) using agarose gel electrophoresis. We passivated QDs with a carboxy-terminated…”
    Get full text
    Journal Article
  8. 8

    Factors determining antibody distribution in tumors by Thurber, Greg M, Schmidt, Michael M, Wittrup, K. Dane

    “…The development of antibody therapies for cancer is increasing rapidly, primarily owing to their specificity. Antibody distribution in tumors is often…”
    Get full text
    Journal Article
  9. 9

    Intratumoral aluminum hydroxide-anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment by Battula, Sailaja, Papastoitsis, Gregory, Kaufman, Howard L, Wittrup, K Dane, Schmidt, Michael M

    Published in JCI insight (08-12-2023)
    “…IL-12 is a potent cytokine that can promote innate and adaptive anticancer immunity, but its clinical development has been limited by toxicity when delivered…”
    Get full text
    Journal Article
  10. 10
  11. 11

    A33 antigen displays persistent surface expression by Ackerman, Margaret E., Chalouni, Cecile, Schmidt, Michael M., Raman, Vivek V., Ritter, Gerd, Old, Lloyd J., Mellman, Ira, Wittrup, K. Dane

    Published in Cancer Immunology, Immunotherapy (01-07-2008)
    “…The A33 antigen is a cell surface glycoprotein of the small intestine and colonic epithelium with homology to tight junction-associated proteins of the…”
    Get full text
    Journal Article
  12. 12

    Zebrafish brd2a and brd2b are paralogous members of the bromodomain-ET (BET) family of transcriptional coregulators that show structural and expression divergence by Dibenedetto, Angela J, Guinto, Jake B, Ebert, Timothy D, Bee, Katharine J, Schmidt, Michael M, Jackman, Todd R

    Published in BMC developmental biology (10-04-2008)
    “…Brd2 belongs to the bromodomain-extraterminal domain (BET) family of transcriptional co-regulators, and functions as a pivotal histone-directed recruitment…”
    Get full text
    Journal Article
  13. 13

    Ultra-High Performance Concrete UHPC: Fundamentals, Design, Examples by Fehling, Ekkehard, Schmidt, Michael, Walraven, Joost, Leutbecher, Torsten, öhlich, Susanne

    Published 2015
    “…Selected chapters from the German concrete yearbook are now being published in the new English "Beton-Kalender Series" for the benefit of an international…”
    Get full text
    eBook
  14. 14

    Abstract 365: Intratumoral delivery of aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response by Battula, Sailaja, Papastoitsis, Gregory, Kaufman, Howard L., Irvine, Darrell J., Wittrup, K. Dane, Schmidt, Michael M.

    Published in Cancer research (Chicago, Ill.) (15-06-2022)
    “…IL-12 is a potent cytokine that mediates anti-tumor immune response, but its clinical development has been hindered by systemic toxicity. Intratumoral (IT)…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    ED operational factors associated with patient satisfaction by Goloback, Molly, MD, McCarthy, Danielle M., MD, MS, Schmidt, Michael, MD, Adams, James G., MD, Pang, Peter S., MD, MSc

    Published in The American journal of emergency medicine (01-01-2015)
    “…Per institutional protocol, 30% of discharged patients are randomly selected to receive the Press Ganey (PG) patient satisfaction survey, a psychometrically…”
    Get full text
    Journal Article